Helixgate

Helixgate

BioPharma Dive – AI / Data

Merck’s deal for Terns sparks debate over a possible biotech bidding war

Published

on

Some investors and analysts believe the pharma’s $6.7 billion offer is justified given Terns’ recent stock run. Others are convinced a better proposal is coming. 

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BioPharma Dive – AI / Data

AstraZeneca lung drug gets ‘surprise’ win in COPD trials

Published

on

The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent. 

Continue Reading

BioPharma Dive – AI / Data

Novartis targets Xolair successor in buyout of startup Excellergy

Published

on

Worth up to $2 billion, the deal is centered around a drug that could lead to faster and more complete control of allergic conditions than Novartis and Roche’s popular medicine. 

Continue Reading

BioPharma Dive – AI / Data

Rocket gene therapy cleared by FDA for rare immune disorder

Published

on

Though the therapy, Kresladi, isn’t seen as a big seller, its clearance is a step forward for a company that’s lost most of its value since 2021 amid several setbacks.  

Continue Reading
Advertisement

Trending